Advancements in Prostate Cancer Treatment: Insights from ESMO Virtual Congress 2020

Advancements in Prostate Cancer Treatment: Insights from ESMO Virtual Congress 2020

Introduction:
The ESMO Virtual Congress 2020 showcased groundbreaking studies and discussions on the latest advancements in prostate cancer treatment. Two notable studies, the PROfound Study and IPATential150, shed light on the potential of biomarker-guided treatments and the prognostic value of 68Ga-PSMA PET/CT scans in guiding salvage radiation treatment. In this article, we will explore the key findings from these studies and discuss their implications for improving overall survival in metastatic castration-resistant prostate cancer (mCRPC) patients.

Biomarker-Guided Treatment: The Future of Prostate Cancer Management:
One of the prominent takeaways from the ESMO Virtual Congress 2020 was the emphasis on biomarker-guided treatment. Dr. Grönberg highlighted the importance of utilizing next-generation sequencing (NGS) to define PTEN-loss, a biomarker associated with poor response to certain treatments. By identifying patients lacking PTEN-loss mutations, Dr. Grönberg recommended avoiding olaparib administration, as it did not demonstrate significant benefits in Cohort B patients lacking these mutations. However, he acknowledged that olaparib could be a viable option for patients with BRCA1 or BRCA2 mutations who have received standard of care treatments.

The Need for Adequate Control Arm in Clinical Trials:
In discussing the PROfound trial results, Dr. Grönberg emphasized the importance of using an appropriate control arm to ensure the generation of clinically relevant data. He expressed concerns about the use of androgen axis targeting agents as the control arm, as previous studies have shown low PSA responses and response rates with this approach. Dr. Grönberg suggested that a more suitable comparison would be the use of cytotoxic chemotherapy to accurately evaluate the efficacy of olaparib.

Prognostic Value of 68Ga-PSMA PET/CT Scans in Salvage Radiation Treatment:
The study on treatment outcomes from 68Ga-PSMA PET/CT-informed salvage radiation treatment after radical prostatectomy provided valuable insights into the prognostic value of this imaging technique. The results indicated that a negative PSMA PET result predicted a high response to salvage fossa radiotherapy, while positive PSMA PET scans indicated poor response to treatment, specifically in cases where there was nodal or distant disease involvement. This finding highlights the potential of PSMA PET in stratifying patients and guiding treatment decisions for optimal therapeutic outcomes.

Actionable Advice:

1. Incorporate Biomarker Testing: Based on the discussions at the ESMO Virtual Congress, it is crucial to incorporate biomarker testing, such as NGS, in the management of prostate cancer. Identifying specific mutations, like PTEN-loss or BRCA1/BRCA2, can help tailor treatment strategies and improve patient outcomes.

2. Consider Alternative Control Arm: When designing clinical trials, it is essential to select an appropriate control arm for accurate evaluation of investigational therapies. Comparing the new treatment to cytotoxic chemotherapy, rather than androgen axis targeting agents, may provide more meaningful data.

3. Utilize PSMA PET Scans for Treatment Planning: In cases of rising PSA after radical prostatectomy, incorporating 68Ga-PSMA PET/CT scans can provide valuable prognostic information for guiding salvage radiation treatment. A negative PSMA PET result may predict a high response to treatment, enabling personalized and targeted therapy planning.

Conclusion:
The ESMO Virtual Congress 2020 highlighted the potential of biomarker-guided treatments and the prognostic value of 68Ga-PSMA PET/CT scans in improving treatment outcomes for mCRPC patients. Incorporating biomarker testing, selecting appropriate control arms in clinical trials, and utilizing PSMA PET scans for treatment planning are actionable strategies that can enhance the precision and effectiveness of prostate cancer management. Continued research and advancements in these areas hold promise for further improving overall survival rates in patients with advanced prostate cancer.